Stockreport

KemPharm Presents Poster at ACNP’s 57th Annual Meeting Highlighting the Intravenous Abuse Potential of Serdexmethylphenidate (SDX)

KemPharm, Inc.  (KMPH) 
Last kempharm, inc. earnings: 2/28 07:30 am Check Earnings Report
US:NASDAQ Investor Relations: investors.kempharm.com/investor-overview
PDF Findings suggest that SDX, a prodrug of d-methylphenidate, is unlikely to be attractive for intravenous abuse CELEBRATION, Fla., Dec. 12, 2018 (GLOBE NEWSWIRE) -- Kem [Read more]